News | September 05, 2025
Quotient Sciences and CPI join forces to accelerate RNA drug development
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content
Subscribe To Our Newsletter & Stay Updated
